Skip to main content

CRISPR Therapeutics

CRISPR Therapeutics AG is a Swiss gene editing biopharmaceutical company developing transformative gene-based medicines utilizing Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR/Cas9) technology. The company commercializes Casgevy for transfusion-dependent beta-thalassemia and severe sickle cell disease in collaboration with Vertex, alongside advancing immuno-oncology and regenerative medicine pipelines. Principal revenues derive from commercial sales of gene therapies, upfront milestone payments, and strategic research partnerships. Core end markets encompass specialized medical centers, hematology treatment facilities, and patients with severe genetic disorders in North America and Europe. CRISPR Therapeutics holds a pioneer market position in the biotechnology industry as the co-developer of the world's first approved CRISPR-based gene editing therapy. The company is headquartered in Zug, Switzerland, and its ordinary shares trade on the Nasdaq Global Select Market.

4 of the funds FundTelligence covers report a position in CRISPR Therapeutics.

Legal name
CRISPR Therapeutics AG
Sector
Health Care
Country
Switzerland
Funds holding it
4
Exposure themes
Gene Editing, Genetic Medicine, Precision Medicine & Genomics

Funds holding CRISPR Therapeutics

Loading...